Australian Natural Therapeutics Group has shut down its research and development unit and made an unspecified […]
ANTG closes in-house R&D department in restructure driven by cost and strategy concerns
The Cannabis Observer
·
FOUNDING MEMBERS
First 100 readers lock in 50% off for life
Sector coverage written for operators, not tourists. Reserve founding-member pricing before launch.
- Weekday briefings on regulation, access schemes, and the companies shaping the market
- Full archive and weekly deep-dives once premium goes live
- 50% off the launch price, locked in for as long as your subscription stays active
Join 87 readers already on the waitlist
Aaron Widdowson
Angel Benares
ANTG
Australian natural therapeutics group
Daniel Harris
Jim Cameron
Justin Sinclair
matt cantelo
R&D
Rick Palesh
SVG Pharm